Media OutReach
BeOne Medicines Honored with the Global Oncology Innovation Leadership Award at BIOHK 2025, Supporting “1+” to Accelerate the Delivery of Innovative Cancer Therapies
Ms. Yiya Chen, General Manager (Taiwan, Hong Kong & Macau) of BeOne, stated, “Receiving the Global Oncology Innovation Leadership Award not only affirms BeOne’s R&D capabilities, but also motivates us to accelerate the transformation of innovative breakthroughs into tangible benefits for patients in the Greater Bay Area, including Hong Kong. Currently, we offer three novel cancer therapies in Hong Kong, covering BTK inhibitor, PD-1 inhibitor, and IL-6 inhibitor. Moving forward, we will proactively leverage the opportunities under the “1+” mechanism to expedite the importation of more international-standard compliant, self-developed medicines, enabling rapid, extensive access to effective treatment for local cancer patients.
Global Research & Development Together with Powered Innovation
Since its establishment in 2010, BeOne has been upholding its mission of “Cancer has no borders. Neither do we,” focusing on developing high-quality, self-developed medicines that meet international standards, with a commitment to accessibility and affordability of innovative cancer treatments. To date, BeOne has conducted over 170 clinical trials across 45 countries and regions, building one of the world’s largest oncology research teams. More than 1.8 million patients have benefited from the achievements of its research and development.
- BTK inhibitor: BeOne’s first independently developed innovative drug, and the only treatment worldwide in its class to have completed head-to-head clinical trials in both Chronic Lymphocytic Leukemia (CLL) and Waldenström’s Macroglobulinemia (WM)1. It has been approved in more than 75 markets and was honored with the prestigious Prix Galien Suisse in 20232..
- PD-1 inhibitor (immunotherapy): Approved in Hong Kong for six indications, including non-small cell lung cancer, esophageal cancer, and gastric cancer, with expansion to nasopharyngeal carcinoma and lung cancer — two of the most prevalent cancer types in Asia. This therapy is marketed in 47 countries and regions including the United States, European Union, China, and Japan, with over 60 indication-approval applications submitted to expand its global coverage.
BeOne’s integrated development approach combines robust R&D capabilities, a PoC-driven strategy and a wide portfolio of assets. With over 40 Phase 3-ready or registration-potential clinical trials and more than 40 R&D assets in clinical and commercialization stages, BeOne maintains leadership across multiple technology platforms, including multi-specific antibodies, chimeric degradation activating compounds (CDACs), and antibody-drug conjugates (ADCs).
Through the PoC strategy, BeOne concentrates on highly differentiated and promising molecule candidates. The company has successfully pushed through the clinical development for 20 drug molecules and obtained regulatory approvals across six continents, demonstrating its outstanding R&D efficiency and globalization strategy.
Globalization to Strengthen Sustainable Supply
BeOne has established three major R&D and manufacturing bases in the United States and China, encompassing the entire industry chain from research and development to manufacturing and commercialization. Notably, the Guangzhou campus spans 1.3 million ft2 and features advanced manufacturing capabilities to produce large-molecule drugs, serving as a core supply hub in the Greater Bay Area, including Hong Kong. This footprint ensures a stable drug supply and enhances accessibility for patients in the region.
As one of the world’s top 20 leading oncology patent holders3 and listed as one of the “World’s Top 10 Most Inventive Pharmaceutical Companies”4 by IDEA Pharma in 2025, BeOne will continue to devote its efforts to researching hematologic and solid tumors. Leveraging Hong Kong as a strategic bridge between Asia and the international community, BeOne is committed to accelerating the development and delivery of innovative therapies, collaboratively driving a new paradigm for cancer care regionally and globally.
Prof. Albert Yu, Chairman of Hong Kong Biotechnology Organization, remarked, “BeOne’s leadership in oncology is fully evident in its innovative drug development, globalization strategy, and significant improvements in quality of life for cancer patients locally and worldwide. Grounded in rigorous scientific research, BeOne aligns clinical needs with accessibility considerations across various markets to launch multiple self-developed innovative medicines to the global stage. The company’s efforts represent scientific excellence and a profound commitment to cancer patients, deserving of the Global Oncology Leadership Award.”
This press release contains forward-looking statements, and actual results may differ from those expressed or implied in these statements. All information provided herein is as of the date of this release, and unless required by law, BeOne has no obligation to update or revise any such information.
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the potential benefits of sonrotoclax; BeOne’s expectations regarding sonrotoclax’s clinical development, regulatory milestones, submissions and approvals; BeOne’s plans to present the full data at an upcoming medical meeting; and BeOne’s plans, commitments, aspirations and goals under the caption “About BeOne.” Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne’s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeOne’s ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne’s ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne’s reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeOne’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products; BeOne’s ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled “Risk Factors” in BeOne’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeOne’s subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeOne undertakes no duty to update such information unless required by law.
[3] Top 50 Pharma: Oncology patent leaders 2024, Drug Discovery & Development
[4] 2025 Pharmaceutical Innovation and Invention Index, IDEA Pharma
Hashtag: #BeOneMedicines
The issuer is solely responsible for the content of this announcement.
About BeOne Medicines
BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of more than 11,000 colleagues spanning six continents, the Company is committed to radically improving access to medicines for far more patients who need them.
To learn more about BeOne, please visit 
www.beonemedicines.com and follow us on LinkedIn, X, Facebook and Instagram.
About BIOHK Hong Kong International Biotechnology Conference & Exhibition
BIOHK Hong Kong International Biotechnology Conference & Exhibition is Asia’s premier biotechnology conference and exhibition. It aims to create a collaborative platform for industry leaders, innovators, and stakeholders to come together and drive the development of biotechnology. BIOHK is dedicated to advancing the biotech sector by not only providing a stage to showcase technological innovations but also offering a launchpad for companies seeking a market expansion to the Greater Bay Area and Mainland China. By combining educational seminars, strategic partnership opportunities, and governmental support, BIOHK empowers participants to foster significant advancements with profound impacts on global health and technology.
The Taiwan-born pet mobility brand opens its first SoHo pop-up inside Flying Solo, bringing its Nordic-designed pet stroller collection to the heart of New York City.
NEW YORK, USA – Media OutReach Newswire – 02 April 2026 – FikaGO, the design-led pet mobility brand recognized across Asia and Europe, has opened its first New York City pop-up store inside Flying Solo in SoHo. The opening marks a deliberate move for a pet brand into one of the world’s most competitive retail districts.
Since entering the online American market in 2025, FikaGO has built a growing community of pet parents who see their animals as a central part of everyday life. Positioned as lifestyle essentials rather than conventional pet gear, FikaGO’s range of products is designed for people who want the best for their fur babies.
“We’ve always believed that pet products should not only be functional, but also beautifully integrated into everyday life.” — Eric Guu, Co-founder, FikaGO
SoHo was a considered choice: Flying Solo, with locations in New York and Paris, is known for championing independent design with a distinctly global sensibility.
The pop-up showcases FikaGO’s auto-folding Free To Go 2 in Sandy Beige, the brand’s bestselling product. All FikaGO’s products are manufactured using eco-friendly fabrics made from recycled materials, reflecting a commitment to sustainability. This includes their large-capacity Agile 2 pet strollers to their airline-approved Truffle carriers and the heavy-duty Kross pet wagon.
“Launching in SoHo is a meaningful milestone for us; it allows customers to truly experience the quality, design, and intention behind every FikaGO product.” — Eric Guu, Co-founder, FikaGO
As pet ownership rises globally, particularly among urban millennials and Gen Zs, demand for products that combine functionality, design, and lifestyle integration continues to grow. FikaGO was built for precisely this moment, and SoHo is precisely where that moment lives.
Visit the FikaGO pop-up at Flying Solo, 419 Broome Street, New York, or explore the full collection at https://us.fikago.com/.
Hashtag: #FikaGO #petmobilitybrand #petstroller #petcarrier #petwagon #petkennel #petbiketrailer
https://us.fikago.com/
https://www.facebook.com/FikaGO.US
https://www.instagram.com/fikago_us/
YouTube: 
https://www.youtube.com/@fikago5910
The issuer is solely responsible for the content of this announcement.
About FikaGO
FikaGO is a pet mobility brand founded in Taiwan, dedicated to crafting products that blend functionality, comfort, and modern aesthetics. With a presence across Asia and growing reach in Europe and the U.S, FikaGO is redefining everyday experiences between pets and their humans.
Media OutReach
Lee Kum Kee Celebrates Culinary Excellence at the Historic Hong Kong Debut of Asia’s 50 Best Restaurants 2026
From 23-25 March, Lee Kum Kee brought together top chefs, diverse cultures and industry communities through a range of thoughtfully curated experiences, bringing authentic Asian flavours to the global stage. As well as reaffirming the brand’s Asian roots and international perspective, its involvement reflected an enduring commitment to preserving culinary heritage and driving gastronomic innovation.
“Asian Flavour Duet“: A Culinary Journey Through Heritage and Innovation
Helping to build momentums for this year’s awards, Lee Kum Kee collaborated with Vicky Cheng, the acclaimed Executive Chef and owner of WING, to co-create the “Asian Flavour Duet”, a Hong Kong-style late-night supper party on 24 March. Hosted at two Hong Kong culinary landmarks, the experience unfolded in two chapters – “Paying Tribute to Heritage” and “Innovative Fusion” – and invited guests to explore the limitless possibilities of Asian flavour.
The evening began at the century-old Lin Heung Lau teahouse, a space filled with nostalgia and memories for generations of Hong Kongers. Chef Vicky reinterpreted classic Hong Kong late-night dishes using signature Lee Kum Kee sauces, while guests were immersed in the warmth of the historic venue.
The celebration then moved to Medora, Chef Vicky’s Western dining space, where an “Innovative Fusion” was revealed. He showcased his modern culinary philosophy by incorporating Lee Kum Kee sauces with contemporary techniques to create bold, unexpected dishes. Guests also enjoyed specially crafted cocktails infused with Lee Kum Kee sauces, alongside a delightful yet refined sauce-inspired gelato, demonstrating a harmonious interweaving of savoury, umami, sweetness and spice.
The multisensory journey seamlessly blended tradition with innovation, exploring the future of cuisine while highlighting Lee Kum Kee’s role as a global gateway to Asian culinary culture.
At the event, Dodie Hung, Executive Vice President – Corporate Affairs at Lee Kum Kee, commented, “Tonight, we are honoured to celebrate Hong Kong’s late‑night food culture with Chef Vicky and the global culinary community. From the legacy of Lin Heung Lau to the forward‑looking spirit of Medora, we are proud to be part of the creative journey and help showcase the depth of Asian flavours on the world stage.”
Celebrating a Gastronomic Brilliance with the Highest Climber Award Sponsored by Lee Kum Kee
During the awards ceremony on 25 March, Lee Kum Kee’s booth showcased a range of the brand’s acclaimed classic sauces and innovative products. Guests sampled specially crafted bites featuring Lee Kum Kee sauces, engaging directly with the flavours and techniques that have made the brand a trusted partner in both home and professional kitchens worldwide.
As part of the evening’s celebration of the region’s most exceptional culinary talents, the Highest Climber Award sponsored by Lee Kum Kee was presented to Lamdre in Beijing by Chef Park from Atomix (No.1 in North America’s 50 Best Restaurants 2025). Lambre was applauded for its pioneering plant-based dining space that promotes healthy, sustainable living while honouring Chinese biodiversity in its menus.
In addition, WING, led by Chef Vicky, achieved an impressive second place in 2026 Asia’s 50 Best Restaurants list. The restaurant had also previously ranked No. 11 on The World’s 50 Best Restaurants list in 2025, underscoring its continued international acclaim.
Building the Future Together: Deepening Global Partnerships
With the success of this prestigious awards ceremony in Hong Kong, China, Lee Kum Kee looks forward to deepening its collaboration with leading talents in the global culinary community. By continuing to champion Asian flavours and foster meaningful dialogue and exchange, the brand will continue to bring the spirit of Asian cuisine to kitchens and dining tables around the world.
Hashtag: #LeeKumKee #LKK
The issuer is solely responsible for the content of this announcement.
About Lee Kum Kee
Lee Kum Kee is the global gateway to Asian culinary culture, dedicated to promoting Chinese culinary culture worldwide. Since 1888, it has brought people together over joyful reunions, shared traditions and memorable meals. Beloved by consumers and chefs alike, Lee Kum Kee’s range of more than 300 sauces and condiments sparks creativity in kitchens everywhere, inspiring professional and home chefs to experiment, create and delight. Headquartered in Hong Kong, China and serving over 100 countries and regions, Lee Kum Kee’s rich heritage, unwavering commitment to quality, sustainable practices and “Constant Entrepreneurship” combine to enable superior experiences through Asian cuisine for people worldwide. For more information, please visit www.LKK.com.
About Asia’s 50 Best Restaurants
Launched in 2013, Asia’s 50 Best Restaurants aims to showcase the outstanding achievements and diverse culinary landscape of the region. The list is determined by the Asia’s 50 Best Restaurants Academy, a panel of over 350 culinary experts from across Asia who vote independently based on their specialised knowledge of the local dining scene. The Asia’s 50 Best Restaurants series includes the awards ceremony and list announcement, creating a premier networking platform for restaurateurs, media, seasoned travelers and culinary connoisseurs to celebrate the exceptional service, passion and talent in the dining industry.
- Herbert Vongpusanachai takes on the role of Senior Vice President for Commercial for the region, effective April 1, 2026
SINGAPORE – Media OutReach Newswire – 2 April 2026 – DHL Express, the world’s leading international express service provider, has appointed Herbert Vongpusanachai as Senior Vice President, Commercial for Asia Pacific, effective April 1, 2026. Herbert, who currently serves as Managing Director for DHL Express Thailand & Indochina, will be based in Singapore for his new role.
Herbert brings more than two decades of leadership experience within DHL Express, having successfully helmed multiple key markets across the region. He first joined the company in 2003 as Managing Director for Thailand & Indochina, later taking on leadership of Singapore in 2008, followed by Hong Kong & Macau in 2016. Since returning to lead Thailand & Indochina in 2020, he has driven sustained year‑on‑year profitable growth, transforming the cluster into one of the region’s key engines of expansion.
“Herbert has an exceptional track record of delivering strong business results while nurturing highly engaged teams across diverse markets. His deep understanding of our customers, collaborative leadership style, and ability to unearth opportunities in complex environments make him the ideal leader to drive our commercial agenda for Asia Pacific. I am confident that under his guidance, we will continue to accelerate sustainable growth across the region,” said Ken Lee, CEO for Asia Pacific, DHL Express.
In his new regional role, Herbert will shape and accelerate the commercial strategy for DHL Express across Asia Pacific by working with other functions to assess new sectors, routes and trade lanes with high potential for growth. He will focus on deepening customer engagement and supporting their expansion, while driving sustainable volume growth and advancing the adoption of new technologies to enhance commercial execution across markets. With his extensive country expertise and people‑first leadership style, Herbert is well‑positioned to support both regional and country teams in raising commercial performance to new levels.
“Asia Pacific remains an important anchor in global trade as seen in the latest DHL Global Connectedness Report, and this indicates the unwavering role of logistics to facilitate the flow of goods. With the newly introduced Heavyweight Express solution, which enables customers to ship heavyweight shipments with speed, certainty and reliability, I look forward to working alongside our talented teams to contribute to shaping the next chapter of DHL Express’s commercial success,” said Herbert Vongpusanachai, Senior Vice President – Commercial for Asia Pacific, DHL Express.
The latest DHL Global Connectedness Report shows that the region remains a major anchor of global commerce, with multiple economies rising in global connectedness rankings and Southeast Asia firmly establishing itself as a fast‑growing trade corridor. This also mirrors one of DHL Group’s strategies to better support 20 markets globally to accelerate growth; eight of them rest in Asia Pacific – underscoring the region’s critical role in DHL’s global network. As trade flows diversify and intra‑Asia integration deepens, this leadership appointment further strengthens DHL Express’s position in Asia Pacific.
Hashtag: #DHL
https://group.dhl.com/en.html
https://www.linkedin.com/company/dhlexpress/
The issuer is solely responsible for the content of this announcement.
DHL – The logistics company for the world
DHL is the leading global brand in the logistics industry. Our DHL divisions offer an unrivalled portfolio of logistics services ranging from national and international parcel delivery, e-commerce shipping and fulfillment solutions, international express, road, air and ocean transport to industrial supply chain management. With approximately 389,000 employees in more than 220 countries and territories worldwide, DHL connects people and businesses securely and reliably, enabling global sustainable trade flows. With specialized solutions for growth markets and industries including technology, life sciences and healthcare, engineering, manufacturing & energy, auto-mobility and retail, DHL is decisively positioned as “The logistics company for the world”.
DHL is part of DHL Group. The Group generated revenues of approximately 82.9 billion euros in 2025. With sustainable business practices and a commitment to society and the environment, the Group makes a positive contribution to the world. DHL Group aims to achieve net-zero emissions logistics by 2050.
-
Feature/OPED6 years agoDavos was Different this year
-
Travel/Tourism10 years ago
Lagos Seals Western Lodge Hotel In Ikorodu
-
Showbiz3 years agoEstranged Lover Releases Videos of Empress Njamah Bathing
-
Banking8 years agoSort Codes of GTBank Branches in Nigeria
-
Economy3 years agoSubsidy Removal: CNG at N130 Per Litre Cheaper Than Petrol—IPMAN
-
Banking3 years agoSort Codes of UBA Branches in Nigeria
-
Banking3 years agoFirst Bank Announces Planned Downtime
-
Sports3 years agoHighest Paid Nigerian Footballer – How Much Do Nigerian Footballers Earn